Piperacillin, Tazobactam Drug Combination — Competitive Intelligence Brief

Piperacillin, Tazobactam Drug Combination (Piperacillin, Tazobactam Drug Combination) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Beta-lactam antibiotic with beta-lactamase inhibitor. Area: Infectious Disease.

marketed Beta-lactam antibiotic with beta-lactamase inhibitor Penicillin-binding proteins (PBPs); beta-lactamase enzymes Infectious Disease Small molecule

Target snapshot

Piperacillin, Tazobactam Drug Combination (Piperacillin, Tazobactam Drug Combination) — Phoenix Children's Hospital. Piperacillin inhibits bacterial cell wall synthesis while tazobactam inhibits beta-lactamase enzymes, allowing piperacillin to kill a broader spectrum of bacteria including beta-lactamase-producing organisms.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Piperacillin, Tazobactam Drug Combination TARGET	Piperacillin, Tazobactam Drug Combination	Phoenix Children's Hospital	marketed	Beta-lactam antibiotic with beta-lactamase inhibitor	Penicillin-binding proteins (PBPs); beta-lactamase enzymes
cefoperazone sodium and sulbactam sodium	cefoperazone sodium and sulbactam sodium	Yung Shin Pharm. Ind. Co., Ltd.	marketed	Beta-lactam antibiotic with beta-lactamase inhibitor	Bacterial penicillin-binding proteins; beta-lactamases
Piperacillin / Tazobactam Injection	Piperacillin / Tazobactam Injection	Rambam Health Care Campus	marketed	Beta-lactam antibiotic with beta-lactamase inhibitor	Penicillin-binding proteins; bacterial beta-lactamase enzymes
high dose amoxicillin/clavulanate	high dose amoxicillin/clavulanate	Albany Medical College	marketed	Beta-lactam antibiotic with beta-lactamase inhibitor	Penicillin-binding proteins (PBPs); beta-lactamase
Amoxycillin/clavulanic acid	Amoxycillin/clavulanic acid	TASK Applied Science	marketed	Beta-lactam antibiotic with beta-lactamase inhibitor	Penicillin-binding proteins (PBPs); bacterial beta-lactamase
Amoxicillin potassium clavulanate	Amoxicillin potassium clavulanate	Kaizen Bioscience Co.	marketed	Beta-lactam antibiotic with beta-lactamase inhibitor	Penicillin-binding proteins (PBPs); bacterial beta-lactamases
Amoxicillin-Potassium Clavulanate Combination	Amoxicillin-Potassium Clavulanate Combination	Universidad Complutense de Madrid	marketed	Beta-lactam antibiotic with beta-lactamase inhibitor	Penicillin-binding proteins (PBPs); bacterial beta-lactamases

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Beta-lactam antibiotic with beta-lactamase inhibitor class)

1. Medical University of Vienna · 2 drugs in this class
2. GlaxoSmithKline · 2 drugs in this class
3. Phoenix Children's Hospital · 2 drugs in this class
4. Albany Medical College · 2 drugs in this class
5. Pfizer · 2 drugs in this class
6. Imperial College London · 1 drug in this class
7. Hospital Italiano de Buenos Aires · 1 drug in this class
8. Bayer · 1 drug in this class
9. Maggiore Bellaria Hospital, Bologna · 1 drug in this class
10. Kaizen Bioscience Co. · 1 drug in this class